Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AGEN | AGENUS INC | 2025-10-16 18:59:29 | 4.05 | 0.06 | 1.5 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGEN | 0001098972 | AGENUS INC | US00847G8042 | 529900NDQQGU5H4UJK81 | 061562417 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 3 FORBES ROAD | LEXINGTON | MA | 02421 | UNITED STATES | US | 781-674-4410 | 3 FORBES ROAD, LEXINGTON, MA, 02421 | 3 FORBES ROAD, LEXINGTON, MA, 02421 | ANTIGENICS INC /DE/ | Biotechnology | 1994 | Garo H. Armen | — | http://www.agenusbio.com | 351,600,000 | 30,004,430 | 31,864,108 | Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. | 2025-10-10 22:46:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 351,600,000 | -231,900,000 | -39.7429 | 25,308,841 | -393,611,230 | -93.9586 |
| 2023 | 583,500,000 | 39,400,000 | 7.2413 | 418,920,071 | 86,406,796 | 25.986 |
| 2022 | 544,100,000 | -685,900,000 | -55.7642 | 332,513,275 | 75,359,415 | 29.3052 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christine M. Klaskin | Vice President | 2024 | 298,224 | 0 | 0 | — | 6,338 | 483,477 |
| Steven J. O’Day | Chief Medical Officer | 2024 | 594,880 | 0 | 0 | — | 10,350 | 968,491 |
| Garo H. Armen | Chief Executive Officer | 2024 | 715,260 | 0 | 0 | — | 56,377 | 3,717,621 |
| Garo H. Armen | Chief Executive Officer | 2023 | 710,499 | 625,000 | 312,500 | — | 0 | 5,856,319 |
| Christine M. Klaskin | Vice President | 2023 | 296,239 | 104,378 | 43,013 | — | 6,822 | 712,747 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 316 |
| 2023 | 389 |
| 2022 | 533 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 103,463,000 | 156,314,000 | 98,024,000 |
| Cost Of Revenue | 486,000 | 3,111,000 | 10,568,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 155,528,000 | 234,569,000 | 186,691,000 |
| General And Administrative Expenses | 71,878,000 | 78,739,000 | 81,007,000 |
| Operating Expenses | 97,000 | 150,000 | — |
| Operating Income | -120,475,000 | -159,549,000 | -179,427,000 |
| Net Income | -232,271,000 | -257,437,000 | -230,656,000 |
| Earnings Per Share Basic | -10.59 | -0.69 | -0.78 |
| Earnings Per Share Diluted | -10.59 | -0.69 | -0.78 |
| Weighted Average Shares Outstanding Basic | 21,473,000 | 357,889 | 281,743 |
| Weighted Average Shares Outstanding Diluted | 21,473,000 | 357,889 | 281,743 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 40,437,000 | 76,110,000 | 178,674,000 |
| Marketable Securities Current | — | — | 14,684,000 |
| Accounts Receivable | 407,000 | 800,000 | 2,741,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,415,000 | 2,372,000 | 3,194,000 |
| Total Assets Current | 45,574,000 | 112,416,000 | 213,122,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 120,087,000 | 133,421,000 | 133,017,000 |
| Other Assets Non Current | 5,834,000 | 9,336,000 | 4,453,000 |
| Total Assets Non Current | 125,921,000 | 142,757,000 | 137,470,000 |
| Total Assets | 226,271,000 | 313,913,000 | 413,556,000 |
| Accounts Payable | 61,470,000 | 61,446,000 | 40,939,000 |
| Deferred Revenue | 31,000 | 18,000 | 12,269,000 |
| Short Term Debt | 2,698,000 | 146,000 | 575,000 |
| Other Liabilities Current | 7,817,000 | 13,915,000 | 11,457,000 |
| Total Liabilities Current | 221,401,000 | 255,897,000 | 188,952,000 |
| Long Term Debt | 33,171,000 | 12,768,000 | 12,584,000 |
| Other Liabilities Non Current | 738,000 | 5,420,000 | 13,826,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 236,000 | 3,944,000 | 3,056,000 |
| Retained Earnings | -2,182,880,000 | -1,955,668,000 | -1,709,907,000 |
| Accumulated Other Comprehensive Income | -1,398,000 | -955,000 | 915,000 |
| Total Shareholders Equity | -326,380,000 | -160,331,000 | -61,278,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 13,343,000 | 13,588,000 | 6,946,000 |
| Share Based Compensation Expense | 17,390,000 | 22,869,000 | 18,337,000 |
| Other Non Cash Income Expense | — | — | 16,300,000 |
| Change In Accounts Receivable | -25,344,000 | 23,461,000 | -122,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,013,000 | 21,366,000 | 6,494,000 |
| Change In Other Liabilities | 691,000 | 1,545,000 | -13,937,000 |
| Cash From Operating Activities | -158,315,000 | -224,202,000 | -175,373,000 |
| Purchases Of Marketable Securities | — | 14,647,000 | 24,629,000 |
| Sales Of Marketable Securities | — | 30,000,000 | 25,000,000 |
| Acquisition Of Property Plant And Equipment | 576,000 | 9,954,000 | 53,062,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 27,000 | 3,400,000 | -33,610,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 33,000,000 | 133,200,000 | 99,200,000 |
| Repurchase Of Common Stock | — | -1,940,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 122,840,000 | 119,866,000 | 95,830,000 |
| Change In Cash | -35,708,000 | -101,564,000 | -113,257,000 |
| Cash At End Of Period | 40,437,000 | 76,110,000 | 178,674,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 2,278,000 | 3,168,000 | 1,143,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -10.59 | -0.69 | -0.78 |
| Price To Earnings Ratio | -0.2587 | -23.9971 | -60.4128 |
| Earnings Growth Rate | 1,434.7826 | -11.5385 | — |
| Price Earnings To Growth Ratio | -0.0002 | 2.0797 | — |
| Book Value Per Share | 0.2268 | 162.1061 | 797.1946 |
| Price To Book Ratio | 12.0813 | 0.1021 | 0.0591 |
| Ebitda | -98,507,000 | -243,849,000 | -223,710,000 |
| Enterprise Value | 54,268,020 | -57,270,073.938 | -152,238,706.354 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.1099 | -0.0805 | -0.2147 |
| Capital Expenditures | 9,000 | 13,992,000 | 79,934,000 |
| Free Cash Flow | -158,324,000 | -238,194,000 | -255,307,000 |
| Return On Equity | 0.7117 | 1.6057 | 3.7641 |
| One Year Beta | 2.7415 | 1.5384 | 1.8531 |
| Three Year Beta | 1.923 | 1.66 | 1.1689 |
| Five Year Beta | 1.3038 | 1.1984 | 1.158 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| ARMEN GARO H | Director | 2025-10-03 | 3,951 | A | 282,393 |
| Wright Timothy | Director | 2025-10-01 | 1,704 | A | 21,872 |
| HARRISON THOMAS L | Director | 2025-10-01 | 5,780 | A | 22,079 |
| ARMEN GARO H | Director | 2025-09-19 | 3,734 | A | 278,442 |
| ARMEN GARO H | Director | 2025-09-05 | 3,778 | A | 274,708 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 19,000 | 4,961 | 3.8299 |
| Key Client Fiduciary Advisors, LLC | 2025-09-30 | 151,047 | 39,233 | 3.85 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 154,189 | 33,740 | 4.5699 |
| WOLVERINE TRADING, LLC | 2025-06-30 | 77,588 | 16,300 | 4.76 |
| Front Row Advisors LLC | 2025-06-30 | 9 | 2 | 4.5 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 109 | 601.68 | 0.0002 |
| VANGUARD EXPLORER FUND | 2025-07-31 | Investor Shares | VEXPX | 290,646 | 1,604,365.92 | 0.0081 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 2025-06-30 | Class K | SSBIX | 551 | 2,518.07 | 0.0004 |
| iSHARES TRUST | 2025-06-30 | iShares Russell 2000 ETF | IWM | 61,070 | 279,089.9 | 0.0004 |
| iSHARES TRUST | 2025-06-30 | iShares Russell 2000 Growth ETF | IWO | 3,062 | 13,993.34 | 0.0001 |